The European Commission has selected a project led by Vall d'Hebron Research Institute (VHIR) that aims to obtain a more effective drug, with a better relation cost-benefit and especially that diminishes the side effects of the current treatments against Chagas's disease. Coordinated by Dr. Israel Molina, member of the research group of infectious diseases at VHIR, the project, called BERENICE, has the participation of prestigious European and South American institutions.Chagas's disease is a chronic disease caused by a parasite, Trypasonoma cruzi. It affects million persons in Latin America, and therefore also to the emigrants of these zones who are in Spain. This endemic disease in Latin America also is transmitted from mother to son during the pregnancy, in transfusions of blood and in transplants of organs. His sharp phase, after the infection, can be unnoticed, since the symptoms that the infected person suffers are generally slight and not specifics.